Work

Abstract CT247: Savolitinib combined with Durvalumab in EGFR wild-type advanced NSCLC patients with MET alterations (SOUND): A multicenter, open-label, Phase II trial

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct247

Authors: Yong-Feng Yu, Xiao-Ying Huang, Qian Chu, An-Wen Liu, Li Zhuang, Xiao-Rong Dong, Hong-Cheng Wu, Jian-Ying Zhou, Shun-Dong Cang, Yan Wang, Yi Hu, Zhen-Zhou Yang, Meng-di Wu, Xiao-yuan Wang, Shun Lu

Institutions: Shanghai Jiao Tong University, Shanghai Chest Hospital, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Tongji Hospital, Huazhong University of Science and Technology, Nanchang University, Second Affiliated Hospital of Nanchang University, Wuhan Union Hospital, Ningbo University, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital Zhejiang University, Zhejiang University, Henan Provincial People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chinese PLA General Hospital, Chongqing University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154726581

Cites:

Cited by:

Related to: